Black Diamond Therapeutics, Inc. (BDTX) stock
BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.43−0.01 (-0.69%)
Close on Nov 18, 2026Market cap $82.16MP/E –Yield –
Black Diamond Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Black Diamond Therapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$62.30M. For fiscal 2024 it was -$62.30M. The highest annual figure on record is -$8.53M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$62.30M | – |
| FY2023 | Dec 31, 2023 | -$66.75M | – |
| FY2022 | Dec 31, 2022 | -$85.27M | – |
| FY2021 | Dec 31, 2021 | -$102.86M | – |
| FY2020 | Dec 31, 2020 | -$52.29M | – |
| FY2019 | Dec 31, 2019 | -$24.70M | – |
| FY2018 | Dec 31, 2018 | -$8.53M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | -$15.06M | – |
| Q4 FY2023 | Dec 31, 2023 | -$13.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$16.47M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$28.61M | – |
| Q4 FY2021 | Dec 31, 2021 | -$24.38M | – |
| Q3 FY2021 | Sep 30, 2021 | -$27.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -$26.01M | – |
| Q1 FY2021 | Mar 31, 2021 | -$24.50M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.88M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.59M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.32M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.49M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.00M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.89M | – |
See a number that looks wrong?